Form 4 for AVBP ArriVent BioPharma, Inc.
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-30 · accession 0001104659-24-008796 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-01-31 | 2024-01-30 | AVBP | HEALY JAMES | Dir | C - Cnv Deriv | — | +1.25M | 1.25M | New | — |
| DI | 2024-01-31 | 2024-01-30 | AVBP | HEALY JAMES | Dir | P - Purchase | $18.00 | +444.4K | 1.70M | +35% | +$8.00M |
| DI | 2024-01-31 | 2024-01-30 | AVBP | HEALY JAMES | Dir | C - Cnv Deriv | — | -1.25M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-30 | C | A | 1,252,308 | — | 1,252,308 | I Sofinnova Venture Partners XI, L.P. | — | — | (F1) The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis. (F2) The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-01-30 | P | A | 444,444 | $18.00 | 1,696,752 | I Sofinnova Venture Partners XI, L.P. | — | — | (F3) Reflects shares purchased in the Issuer's initial public offering. (F2) The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. |
| 3 | Derivative | Series B Preferred Stock | 2024-01-30 | C | D | 1,252,308 | — | 0 | I Sofinnova Venture Partners XI, L.P. | — · — to — | 1,252,308 Common Stock | (F1) The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-15.21 basis. (F2) The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein. (F4) The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. (F5) Not applicable. |